Mira Hellmann, MD, gynecologic oncologist and assistant professor, Hackensack Meridian John Theurer Cancer Center at Hackensack University Medical Center, discusses using trametinib (Mekinist) to treat patients with low-grade ovarian serous carcinomas.

Patients with low-grade ovarian serous carcinomas are difficult to treat because they are often chemotherapy-resistant and are usually treated with hormonal therapy or sometimes chemotherapy with little yield, explains Hellmann.

The GOG-0281 trial examined patients with low-grade serous tumors and compared treatment with hormonal therapy versus chemotherapy versus the MEK inhibitor trametinib. The trametinib arm showed an improvement in progression-free survival, giving this patient population a new treatment option, concludes Hellmann.

Videos

Mira Hellmann, MD, discusses using trametinib to treat patients with low-grade ovarian serous carcinomas.

Dr. Hellmann on Using Trametinib in Low-Grade Ovarian Serous Carcinoma

Mira C. Hellmann, MD, gynecologic oncologist and assistant professor, John Theurer Cancer Center, Hackensack University Medical Center, discusses the benefit of PARP inhibitors in patients with ovarian cancer.

There have not been many breakthroughs in treatment options for patients with ovarian cancer. However, one larger finding that has been discovered is PARP inhibitors, which has shown benefit for select patients with ovarian cancer. Studies have shown that patients treated with PARR inhibitors experienced a significant improvement in their disease status, says Hellmann.

PARP inhibitors were originally thought to be limited to patients with a BRCA1/2 mutation but there have been more studies that have demonstrated efficacy in patients who do not have the BRCA1/2mutation but are positive for homologous recombination deficiency (HRD). There has also been research that found efficacy of PARP inhibitors in patients who have HRD-positive disease, as well as, those who do not have a BRCA1/2 mutation nor HRD-positive disease, concludes Hellmann.

Mira C. Hellmann, MD, discusses the benefit of PARP inhibitors in patients with ovarian cancer.
 

Mira C. Hellmann, MD

Articles

Dr. Hellmann on Using Trametinib in Low-Grade Ovarian Serous Carcinoma

Dr. Hellmann on Benefit of PARP Inhibitors in Patients With Ovarian Cancer